Figures computed from official regulatory filings — .
Analysttarget 68 USD (+4344%) · consensus 4/5 · 2 buy · 2 hold · 0 sell
Ownershipinsiders 4.24% · institutions 46.12% · short 4.7% of float
In USD · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Skye Bioscience, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.
Market information source · Oct 19, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 19, 2026
Open-market timeline · full history
7 buys64 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| 5AM Partners VII, LLC | Sell | $1.8K | SEC |
| Schwab Andrew J. | Sell | $45.6K | SEC |
| 5AM Partners VII, LLC | Sell | $7.3K | SEC |
| Schwab Andrew J. | Sell | $1.8K | SEC |
| Schwab Andrew J. | Sell | $7.3K | SEC |
| 5AM Partners VII, LLC | Sell | $45.6K | SEC |
| 5AM Partners VII, LLC | Sell | $184.9K | Unusual size | SEC |
| Schwab Andrew J. | Sell | $184.9K | SEC |
| Schwab Andrew J. | Sell | $2.5K | SEC |
| 5AM Partners VII, LLC | Sell | $2.5K | SEC |
| 5AM Partners VII, LLC | Sell | $62.3K | SEC |
| Schwab Andrew J. | Sell | $62.3K | SEC |
| Schwab Andrew J. | Sell | $3.6K | SEC |
| Schwab Andrew J. | Sell | $143.1 | SEC |
| Schwab Andrew J. | Sell | $20.1K | SEC |
| Schwab Andrew J. | Sell | $2.1K | SEC |
| Schwab Andrew J. | Sell | $96.2K | SEC |
| 5AM Partners VII, LLC | Sell | $14.7 | SEC |
| Schwab Andrew J. | Sell | $695.4 | SEC |
| 5AM Partners VII, LLC | Sell | $96.2K | SEC |
| 5AM Partners VII, LLC | Sell | $3.6K | SEC |
| Schwab Andrew J. | Sell | $17.1K | SEC |
| 5AM Partners VII, LLC | Sell | $370.9 | SEC |
| Schwab Andrew J. | Sell | $370.9 | SEC |
| 5AM Partners VII, LLC | Sell | $17.1K | SEC |